Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.47 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.41 |
| ▸ | SETD7 | Q8WTS6 | 2/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135245 | 1.00 | SMARCA2 (0.47) | SMARCA2SMARCA4PBRM1GPR119SETD7 | |
| SCHEMBL135248 | 1.00 | SMARCA2 (0.47) | SMARCA2SMARCA4PBRM1GPR119SETD7 | |
| SCHEMBL135246 | 1.00 | SMARCA2 (0.47) | SMARCA2SMARCA4PBRM1GPR119SETD7 | |
| SCHEMBL103728 | 0.90 | SMARCA2 (0.46) | SMARCA2SMARCA4PBRM1GPR119SETD7 | |
| SCHEMBL106647 | 0.86 | GPR119 (0.44) | SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL106646 | 0.86 | GPR119 (0.44) | SMARCA2SMARCA4PBRM1GPR119 | |
| SCHEMBL105833 | 0.85 | GPR119 (0.40) | SMARCA2SMARCA4PBRM1GPR119SETD7 | |
| SCHEMBL105834 | 0.85 | GPR119 (0.40) | SMARCA2SMARCA4PBRM1GPR119SETD7 | |
| SCHEMBL105835 | 0.85 | GPR119 (0.40) | SMARCA2SMARCA4PBRM1GPR119SETD7 | |
| SCHEMBL106302 | 0.85 | GPR119 (0.40) | SMARCA2SMARCA4PBRM1GPR119SETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426113-B1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | KOWA CO (JP) | 2013-11-06 | — | — | EP | disclosed |
| US-8551985-B2 | Carbinol derivatives having heterocyclic linker | KOWA COMPANY, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2426113-A1 | CARBINOL COMPOUND HAVING HETEROCYCLIC LINKER | Kowa Company, Ltd. (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280013-A1 | CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER | NR1H2, NR1H3, CCR2 | SMARCA2 2083/4885SMARCA4 2434/4885PBRM1 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.